A new company focused on obesity and cardiometabolic disorders was launched on 9 January with $411 million in a Series A venture financing. Named Verdiva Bio Ltd the company is registered in the UK with leadership in Europe and North America and a start-up portfolio from China. The company’s financing syndicate is co-led by Forbion of the Netherlands and the US private equity group General Atlantic with five other participants including Lilly Asia Ventures.
